Will a New Insomnia Drug Be the Next Blockbuster?

Merck, the pharmaceutical company has developed a new insomnia drug that could replace leading competitors such as Ambien. Suvorexant, the new sleeping pill that the company has been developing for a decade, was proved to be safe and effective. The FDA was to approve the new drug and if the government approved suvorexant, it would be launched within a year.

Some industry analysts had described the new drug as a possible blockbuster, a term usually reserved for drugs with annual earnings of a billion dollars.

However, during an FDA presentation, suvorexant was presented as disquieting and linked to suicidal thoughts among its trial participants. There was also a risk of next-day sleepiness. Patient notes stated that a participant “had a dream that something dark approached her. The patient woke up several times and felt unable to move her arms and legs and unable to speak. Several hours later, she found herself standing at the window without knowing how she got there.” A middle-aged man had a “feeling of shadow falling over his body, hunted by enemies, hearing extremely loud screams.”

These kinds of effects and adverse events are discouraging to a drug’s sponsor. However, Merck’s marketing is likely to encourage the perception that suvorexant ends insomnia by standing in the way of a keep-awake signal, whereas a drug like Ambien knocks the user out senseless, promoting stupefying brain inactivity.

If you or a loved one has been seriously injured as a result of taking a dangerous or recalled drug, contact us today. We’re here to help.

Read more about this new drug.

Dear friends and clients,

In furtherance of our firms culture of commitment to always act with compassion, concern and commitment to our clients, community and colleagues, we have been taking precautions to ensure that we are still fulfilling our ethical and moral obligations while prioritizing health, wellness and safety of all we can. 

As you know, the COVID-19 pandemic has introduced changes to many lives and businesses in our communities, and around the world. We, much like our neighbors and friends, have been taking precautions to ensure that we are still fulfilling our ethical and moral obligation to our clients, while also prioritizing the health, wellness and safety of our employees.

Until further notice, our offices will be closed to the public to encourage social distancing and to help prevent the spread of COVID-19. Our team is still hard at work, many from home, and you may still call, email, live chat or video conference us if you or a loved one is seeking legal assistance. As the first law firm to offer our clients secure online access to their case file more than a decade ago, we have always been believers in using technology to make life easier and information more accessible. In these present times it has been a smooth transition for us to continue to offer our clients the same seamless and thorough service that you deserve and are accustomed to.

This pandemic is unlike anything any of us have faced in our lifetimes, and while we can continue to emotionally support one another through it all, staying home and keeping your distance is vital to the health and wellness of our communities. It does not feel good to break routines, cancel events and retreat from our normal, day-to-day socializing, but let us remember that, in times of strife, prior generations were asked to go to war and we are simply being asked to stay home. Your isolation equals more lives saved, and more time for medical providers to prepare for the treatment of patients battling COVID-19.

When the dust settles, we will join together with a greater appreciation for our lives, local businesses, loved ones and health. Until then, we will continue to offer guidance from a safe distance.

Very truly yours,

Andrew G. Finkelstein and the staff of Jacoby & Meyers, LLP